Patient Education
Share your love
Visionix Unveils VX 650 Multimodal Screener
Visionix has announced the release of the second generation of its VX 650 multimodal device. First launched in 2021, the VX 650 is an advanced anterior segment analyzer with retinal imaging capabilities. The updated version features an enhanced wavefront-based aberrometer…
Apellis’ Syfovre for Treatment of GA Approved by FDA
The FDA has approved Apellis Pharmaceuticals’ Syfovre (pegcetacoplan) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). This marks the first time that patients with GA have an FDA-approved treatment option, which is a significant milestone…
Benefits Of Combination Drops On Glaucoma Management
When patients are diagnosed with glaucoma, one of the most common treatment options is a prescription eye drop medication that lowers eye pressure, which prevents damage to the optic nerve and helps to preserve vision. Several types of drugs lower…
J&J announced new products at the AAO annual meeting
Johnson & Johnson Vision announced a series of new products and innovations at the 2019 American Academy of Ophthalmology (AAO) Annual Meeting in San Francisco, CA, USA. The company announced the US Food & Drug Administration (FDA) approval of the…
Updates On Central Serous Chorioretinopathy
Central serous chorioretinopathy, commonly referred to as CSC, is a condition in which fluid accumulates under the retina, causing a serous (fluid-filled) detachment and vision loss. CSC most often occurs in young and middle-aged adults. For unknown reasons, men develop…
Topcon and OphtAI Collaborate for AI Technology
Topcon Healthcare Solutions and OphtAI, a joint venture specialized in Artificial Intelligence (AI) for ophthalmology, have announced a partnership to integrate OphtAI into Topcon’s Harmony Referral System, and provide eye care professionals with smarter access to AI services. OphtAI’s state-of-the-art…
ELITA Femtosecond Laser System Receives CE Mark
Johnson & Johnson Vision has announced that they have received CE Mark approval for the ELITA Femtosecond Laser System. The laser is designed to perform refractive correction on patients with myopia, with or without astigmatism, using the SILK (Smooth Incision…
Amsler Grid Found Ineffective for Neovascular AMD
According to a recent systematic review and meta-analysis published online on Feb. 16 in JAMA Ophthalmology, the Amsler grid has a 67 percent sensitivity for detecting neovascular age-related macular degeneration (AMD) when compared with healthy controls. In a systematic literature…
Frontera’s Trial for Retinitis Pigmentosa Kicks Off
Frontera Therapeutics has initiated a clinical trial for its gene therapy, FT-002, which is intended for the treatment of X-linked retinitis pigmentosa (XLRP). The first patient has already been given a dose of the gene therapy product. FT-002 is Frontera’s…
Complement Therapeutics Begins i-GAIN Study
Complement Therapeutics has made an announcement about the enrollment of the first participant in the i-GAIN study, a research project aimed at gaining insight into geographic atrophy (GA) – a condition that results in irreversible blindness and is caused by…